Prevention of Life-Threatening Ventricular Tachyarrhythmia by a Novel and Pure Class-III Agent, Nifekalant Hydrochloride
Authors:
- Satoshi YasudaSYSatoshi Yasuda
- Shunichi MiyazakiSMShunichi Miyazaki
- Wataru ShimizuWSWataru Shimizu
- Isao MoriiIMIsao Morii
- Takashi KuritaTKTakashi Kurita
- Atsushi KawamuraAKAtsushi Kawamura
- Shiro KamakuraSKShiro Kamakura
- Hiroshi NonogiHNHiroshi Nonogi
- 1 December 2006
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 48 (6) , 274-279
Abstract
Nifekalant hydrochloride (NIF) is a novel intravenous class-III antiarrhythmic agent with a pirimidinedione structure that purely blocks the K+channel without inhibiting β-adrenergic receptors. The authors investigated the efficacy of NIF for refractory ventricular tachycardia/fibrillation (VT/VF). They studied 30 patients treated with an intravenous infusion of NIF [ 26 men, 4 women; age: 63 ± 17 (mean ± SD) years] at a dose of 0.19 ± 0.14 mg/kg body weight per hour. Sixteen were patients with acute coronary syndrome (ACS), and 14 were patients with chronic structural heart disease (Chr-HD). Amiodarone and sotalol had already been administered to 9 patients with Chr-HD before the administration of NIF. The QT and T peak-end (Tp-e) intervals were measured and corrected by Bazett's method (QTc, cTp-e). The left ventricular ejection fraction was depressed (28 ± 9%). NIF was effective for preventing VT/VF without proarrhythmia and hemodynamic deterioration in 21 patients (70%; 12 with ACS; 9 with Chr-HD), but ineffective in 4 patients (all with Chr-HD). The QTc prolongation in the responders was more pronounced than in the nonresponders (25% ± 15% versus 5% ± 7% increase; P < 0.05). Proarrhythmic torsade de pointes (TdP) developed transiently in the remaining 5 patients in whom the cTp-e was markedly increased compared with that in the responders (93% ± 49% versus 37% ± 41% increase; P < 0.05). In conclusion, these findings indicate that the intravenous administration of NIF is useful in the emergent treatment of inhibiting drug-refractory VT/VF, although proarrhythmic TdP owing to an enhancement of transmural dispersion of repolarization needs to be taken into account.Keywords
This publication has 15 references indexed in Scilit:
- Intravenous Administration of Nifekalant Hydrochloride for the Prevention of Ischemia-Induced Ventricular Tachyarrhythmia in Patients With Renal Failure Undergoing HemodialysisCirculation Journal, 2003
- The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogsJACC, 2002
- Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug.Folia Pharmacologica Japonica, 2002
- Initial Experience With Nifekalant Hydrochloride (MS-551), A Novel Class III Antiarrhythmic Agent, in Patients With Acute Extensive Infarction and Severe Ventricular DysfunctionJapanese Circulation Journal, 2001
- Acute Electropharmacological Effects of Intravenously Administered Amiodarone Assessed in the In Vivo Canine ModelThe Japanese Journal of Pharmacology, 2001
- Sodium Channel Block With Mexiletine Is Effective in Reducing Dispersion of Repolarization and Preventing Torsade de Pointes in LQT2 and LQT3 Models of the Long-QT SyndromeCirculation, 1997
- Can a Class III Antiarrhythmic Drug Improve Electrical Defibrillation Efficacy During Ventricular Fibrillation?JACC, 1997
- Dose-Ranging Study of Intravenous Amiodarone in Patients With Life-Threatening Ventricular TachyarrhythmiasCirculation, 1995
- Cellular electrophysiological effects of MS‐551, a new class III antiarrhythmic agentDrug Development Research, 1995
- Effects of MS-551, a New Class III Antiarrhythmic Drug, on Programmed Stimulation-Induced Ventricular Arrhythmias, Electrophysiology, and Hemodynamics in a Canine Myocardial Infarction ModelJournal of Cardiovascular Pharmacology, 1994